BnnBnn interviewed the author of the Financial Times article this morning. He didn't think we'd be taken in for hearings in parliament, but figured regulators would likely be looking into the price hikes. Just when you think headline risk is gone a new one arises. I thought this name would eventually decouple from Valeant, but it looks like the media is going to paint us with the same brush rightly or wrongly. Public perception is at an all time low for Turing and Valeant, and it seems the media is going to use their big reach to make Concordia the next pharma bad boy to keep these headlines going. Brutal...........